FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894051390> ?p ?o ?g. }

• W2894051390 endingPage "2248" @default.
• W2894051390 startingPage "2240" @default.
• W2894051390 abstract "Abstract The combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL) to determine the maximal tolerated dose (MTD) of POM as the primary objective, and overall response rate (ORR), progression-free survival (PFS), and safety profile as secondary objectives. A cohorts-of-3 study design was used with a dose-escalation schedule consisting of POM (3, 5, 7, or 10 mg) orally daily for 21 days every 28 days and DEX 40 mg orally every week. After 2 cycles, POM was continued alone until disease progression, intolerance, or subject withdrawal. Following MTD determination, the MTD cohort was expanded. Twenty-five of 29 patients with the median of 3 prior treatments were eligible for assessment as per international PCNSL collaborative group criteria. The MTD of POM was 5 mg daily for 21 days every 28 days. Whole-study ORR was 48% (12 of 25; 95% confidence interval [CI], 27.8%, 68.7%) with 6 complete response (CR), 2 complete response, unconfirmed (CRu), and 4 partial response (PR). MTD cohort ORR was 50% (8 of 16; 95% CI, 24.7%, 75.4%) with 5 CR, 1 CRu, and 2 PR. Median PFS was 5.3 months (whole study) and 9 months (for responders). One patient had pseudoprogression. Grade 3/4 hematologic toxicities included neutropenia (21%), anemia (8%), and thrombocytopenia (8%). Grade 3/4 nonhematologic toxicities included lung infection (12%), sepsis (4%), fatigue (8%), syncope (4%), dyspnea (4%), hypoxia (4%), respiratory failure (8%), and rash (4%). POM/DEX treatment is feasible with significant therapeutic activity against relapsed/refractory PCNSL and PVRL. This trial was registered at www.clinicaltrials.gov as #NCT01722305." @default.
• W2894051390 created "2018-10-05" @default.
• W2894051390 creator A5004152557 @default.
• W2894051390 creator A5004573264 @default.
• W2894051390 creator A5008761191 @default.
• W2894051390 creator A5023657472 @default.
• W2894051390 creator A5023905352 @default.
• W2894051390 creator A5026397451 @default.
• W2894051390 creator A5027267415 @default.
• W2894051390 creator A5027394636 @default.
• W2894051390 creator A5028356321 @default.
• W2894051390 creator A5033270808 @default.
• W2894051390 creator A5052702492 @default.
• W2894051390 creator A5060317624 @default.
• W2894051390 creator A5076892547 @default.
• W2894051390 creator A5082704917 @default.
• W2894051390 date "2018-11-22" @default.
• W2894051390 modified "2023-10-11" @default.
• W2894051390 title "Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma" @default.
• W2894051390 cites W1545029456 @default.
• W2894051390 cites W1971305591 @default.
• W2894051390 cites W1973020397 @default.
• W2894051390 cites W1989124191 @default.
• W2894051390 cites W1993330306 @default.
• W2894051390 cites W2028038779 @default.
• W2894051390 cites W2045399297 @default.
• W2894051390 cites W2054383376 @default.
• W2894051390 cites W2057239581 @default.
• W2894051390 cites W2066815159 @default.
• W2894051390 cites W2094380867 @default.
• W2894051390 cites W2111322227 @default.
• W2894051390 cites W2115623838 @default.
• W2894051390 cites W2135860817 @default.
• W2894051390 cites W2136541422 @default.
• W2894051390 cites W2139836848 @default.
• W2894051390 cites W2149603266 @default.
• W2894051390 cites W2152428953 @default.
• W2894051390 cites W2163393078 @default.
• W2894051390 cites W2314481096 @default.
• W2894051390 cites W2318630604 @default.
• W2894051390 cites W2600468195 @default.
• W2894051390 cites W2600581432 @default.
• W2894051390 cites W2601571543 @default.
• W2894051390 cites W2605009867 @default.
• W2894051390 cites W2605767476 @default.
• W2894051390 cites W2618939391 @default.
• W2894051390 cites W2662929969 @default.
• W2894051390 cites W2780889590 @default.
• W2894051390 cites W2979333626 @default.
• W2894051390 cites W94592798 @default.
• W2894051390 doi "https://doi.org/10.1182/blood-2018-02-835496" @default.
• W2894051390 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6265643" @default.
• W2894051390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30262659" @default.
• W2894051390 hasPublicationYear "2018" @default.
• W2894051390 type Work @default.
• W2894051390 sameAs 2894051390 @default.
• W2894051390 citedByCount "84" @default.
• W2894051390 countsByYear W28940513902018 @default.
• W2894051390 countsByYear W28940513902019 @default.
• W2894051390 countsByYear W28940513902020 @default.
• W2894051390 countsByYear W28940513902021 @default.
• W2894051390 countsByYear W28940513902022 @default.
• W2894051390 countsByYear W28940513902023 @default.
• W2894051390 crossrefType "journal-article" @default.
• W2894051390 hasAuthorship W2894051390A5004152557 @default.
• W2894051390 hasAuthorship W2894051390A5004573264 @default.
• W2894051390 hasAuthorship W2894051390A5008761191 @default.
• W2894051390 hasAuthorship W2894051390A5023657472 @default.
• W2894051390 hasAuthorship W2894051390A5023905352 @default.
• W2894051390 hasAuthorship W2894051390A5026397451 @default.
• W2894051390 hasAuthorship W2894051390A5027267415 @default.
• W2894051390 hasAuthorship W2894051390A5027394636 @default.
• W2894051390 hasAuthorship W2894051390A5028356321 @default.
• W2894051390 hasAuthorship W2894051390A5033270808 @default.
• W2894051390 hasAuthorship W2894051390A5052702492 @default.
• W2894051390 hasAuthorship W2894051390A5060317624 @default.
• W2894051390 hasAuthorship W2894051390A5076892547 @default.
• W2894051390 hasAuthorship W2894051390A5082704917 @default.
• W2894051390 hasBestOaLocation W28940513901 @default.
• W2894051390 hasConcept C121332964 @default.
• W2894051390 hasConcept C126322002 @default.
• W2894051390 hasConcept C141071460 @default.
• W2894051390 hasConcept C142424586 @default.
• W2894051390 hasConcept C2776063141 @default.
• W2894051390 hasConcept C2776694085 @default.
• W2894051390 hasConcept C2777063308 @default.
• W2894051390 hasConcept C2778524551 @default.
• W2894051390 hasConcept C2778570526 @default.
• W2894051390 hasConcept C2778850193 @default.
• W2894051390 hasConcept C2780401358 @default.
• W2894051390 hasConcept C71924100 @default.
• W2894051390 hasConcept C72563966 @default.
• W2894051390 hasConcept C87355193 @default.
• W2894051390 hasConcept C90924648 @default.
• W2894051390 hasConceptScore W2894051390C121332964 @default.
• W2894051390 hasConceptScore W2894051390C126322002 @default.
• W2894051390 hasConceptScore W2894051390C141071460 @default.
• W2894051390 hasConceptScore W2894051390C142424586 @default.

• next